ATE204468T1 - Mittel zur verzögerten freisetzung von menschlichem wachstumshormon - Google Patents

Mittel zur verzögerten freisetzung von menschlichem wachstumshormon

Info

Publication number
ATE204468T1
ATE204468T1 AT96919016T AT96919016T ATE204468T1 AT E204468 T1 ATE204468 T1 AT E204468T1 AT 96919016 T AT96919016 T AT 96919016T AT 96919016 T AT96919016 T AT 96919016T AT E204468 T1 ATE204468 T1 AT E204468T1
Authority
AT
Austria
Prior art keywords
composition
hgh
biologically active
sustained release
polymer
Prior art date
Application number
AT96919016T
Other languages
English (en)
Inventor
Olufunmi Lily Johnson
Medha M Ganmukhi
Howard Bernstein
Henry Auer
M Amin Khan
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,725 external-priority patent/US5667808A/en
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ATE204468T1 publication Critical patent/ATE204468T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT96919016T 1995-06-07 1996-06-03 Mittel zur verzögerten freisetzung von menschlichem wachstumshormon ATE204468T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/477,725 US5667808A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
US08/473,544 US5654010A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
PCT/US1996/008086 WO1996040072A2 (en) 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone

Publications (1)

Publication Number Publication Date
ATE204468T1 true ATE204468T1 (de) 2001-09-15

Family

ID=27044171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919016T ATE204468T1 (de) 1995-06-07 1996-06-03 Mittel zur verzögerten freisetzung von menschlichem wachstumshormon

Country Status (22)

Country Link
EP (1) EP0831787B1 (de)
JP (1) JPH11506740A (de)
CN (1) CN1102854C (de)
AT (1) ATE204468T1 (de)
AU (1) AU708756B2 (de)
BR (1) BR9608542A (de)
CA (1) CA2223436A1 (de)
CZ (1) CZ288147B6 (de)
DE (1) DE69614685T2 (de)
DK (1) DK0831787T3 (de)
ES (1) ES2161366T3 (de)
HK (1) HK1009089A1 (de)
HU (1) HUP9900870A3 (de)
IL (1) IL122385A (de)
MX (1) MX9709698A (de)
NO (1) NO316104B1 (de)
NZ (1) NZ310644A (de)
PL (1) PL184531B1 (de)
PT (1) PT831787E (de)
RU (1) RU2161502C2 (de)
SK (1) SK281571B6 (de)
WO (1) WO1996040072A2 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6242096A (en) * 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
EP2050762A3 (de) 1998-03-10 2009-07-08 Genentech, Inc. Neue Polypeptide und für diese kodierende Nukleinsäuren
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
DE60043322D1 (de) 1999-06-15 2009-12-24 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
EP1666495A1 (de) 1999-12-01 2006-06-07 Genentech, Inc. Sekretierte und Transmembran-Polypeptide und für diese kodierende Nukleinsäuren
EP1897946B1 (de) 1999-12-23 2012-07-11 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
EP1246917B1 (de) 2000-01-13 2009-03-04 Genentech, Inc. Menschliche stra6 polypeptide
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
EP1265630B1 (de) 2000-03-24 2006-06-07 Genentech, Inc. Verwendung von insulin zur behandlung von knorpelkrankheiten
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2014298A3 (de) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22-Polypeptide, Nukleinsäuren zu deren Codierung und Verfahren zur Behandlung von Bauchspeicheldrüsenerkrankungen
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
CA2680475A1 (en) 2000-12-28 2002-07-11 Shigeyuki Takada Sustained-release preparation
WO2002092619A2 (en) 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DK1397155T3 (en) 2001-06-21 2015-12-07 Genentech Inc Prolonged release formulation
SI1485477T1 (sl) 2002-02-25 2009-10-31 Genentech Inc Novi citokinski receptor GLM-R tipa 1
EP2335725B1 (de) 2003-04-04 2016-10-12 Genentech, Inc. Hochkonzentrierte Antikörper- und Proteinformulierungen
EP1636593B9 (de) 2003-06-06 2009-12-16 Genentech, Inc. Modulation der wechselwirkung zwischen hgf-beta-kette und c-met
SI2784084T2 (sl) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
JP2008507252A (ja) 2003-12-11 2008-03-13 ジェネンテック・インコーポレーテッド Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
EP2289911A3 (de) 2004-03-30 2011-03-30 NsGene A/S Therapeutische Verwendung des Wachstumsfaktors nsg33
NZ554559A (en) 2004-10-27 2010-05-28 Univ Florida Adrenocorticotropic hormone (ACTH) analogs and related methods
US20060153786A1 (en) 2004-12-10 2006-07-13 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
ES2569917T3 (es) 2005-06-21 2016-05-13 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2007024628A2 (en) 2005-08-24 2007-03-01 The Rockefeller University Ply-gbs mutant lysins
ZA200804162B (en) 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
RU2385877C1 (ru) 2005-12-22 2010-04-10 Дженентек, Инк. Рекомбинантное получение связывающих гепарин белков
EP2050335A1 (de) 2006-02-17 2009-04-22 Genentech, Inc. Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
EP2389948A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
ES2385261T3 (es) 2006-04-10 2012-07-20 Genentech, Inc. Moduladores de PDZ Disheveled
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
US8323688B2 (en) * 2006-08-31 2012-12-04 Novartis Ag Pharmaceutical compositions comprising hGH for oral delivery
MX2009006709A (es) 2006-12-20 2009-07-02 Xoma Technology Ltd Tratamiento de enfermedades relacionadas con il-1beta.
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
AU2008343085B2 (en) 2007-12-20 2015-03-12 Xoma (Us) Llc Methods for the treatment of gout
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
WO2011047267A1 (en) 2009-10-15 2011-04-21 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
US8936804B2 (en) 2010-01-15 2015-01-20 Rutgers, The State University Of New Jersey Use of vanadium compounds to accelerate bone healing
JP5937059B2 (ja) 2010-03-22 2016-06-22 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化に有用な組成物及び方法
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
EP2585045B1 (de) 2010-06-24 2019-08-21 F.Hoffmann-La Roche Ag Alkylglykoside enthaltende zusammensetzungen und verfahren zur stabilisierung von proteinhaltigen formulierungen
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN108079279B (zh) 2010-10-01 2022-04-12 霍巴治疗公司 镍纹蛋白用于治疗异常性疼痛、痛觉过敏、自发性疼痛和幻痛的用途
WO2012045281A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CN102875683B (zh) * 2011-07-11 2014-06-11 旭华（上海）生物研发中心有限公司 长效重组人生长激素的Fc融合蛋白
KR20140084078A (ko) 2011-10-31 2014-07-04 제넨테크, 인크. 항체 제제
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP2016514024A (ja) 2013-03-14 2016-05-19 ハラックス，インコーポレイテッド 爪部の感染症、疾患または障害の治療方法
CA2903091C (en) 2013-03-15 2022-09-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
EP3022224A2 (de) 2013-07-18 2016-05-25 Fabrus, Inc. Antikörper mit ultralangen komplementaritätsbestimmenden regionen
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
EP3043824B1 (de) 2013-09-13 2022-07-06 The Scripps Research Institute Modifizierte therapeutische mittel und zusammensetzungen daraus
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
JP6637415B2 (ja) 2013-10-15 2020-01-29 ザ スクリプス リサーチ インスティテュート キメラ抗原受容体ｔ細胞スイッチおよびその使用
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
AU2017345479B2 (en) 2016-10-19 2024-03-21 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
KR20210145152A (ko) 2019-04-01 2021-12-01 제넨테크, 인크. 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
MX2022001732A (es) 2019-08-12 2022-05-06 Purinomia Biotech Inc Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
CA3217602A1 (en) 2021-05-06 2022-11-10 Kenneth Petersen Prevention and treatment of chemotherapy-induced neuropathic pain
AU2022405685A1 (en) 2021-12-10 2024-07-11 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
EP0674506B1 (de) * 1992-12-02 2000-08-23 Alkermes Controlled Therapeutics, Inc. Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
ATE197398T1 (de) * 1994-09-09 2000-11-11 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freigabe eines metallsalz eines peptids

Also Published As

Publication number Publication date
NO316104B1 (no) 2003-12-15
EP0831787B1 (de) 2001-08-22
HUP9900870A3 (en) 2001-04-28
HUP9900870A2 (hu) 1999-09-28
NO975708L (no) 1998-02-05
CZ390797A3 (cs) 1998-07-15
HK1009089A1 (en) 1999-09-10
JPH11506740A (ja) 1999-06-15
WO1996040072A2 (en) 1996-12-19
SK167197A3 (en) 1998-06-03
AU708756B2 (en) 1999-08-12
PL323832A1 (en) 1998-04-27
NZ310644A (en) 1999-08-30
RU2161502C2 (ru) 2001-01-10
CN1187120A (zh) 1998-07-08
EP0831787A2 (de) 1998-04-01
CA2223436A1 (en) 1996-12-19
SK281571B6 (sk) 2001-05-10
PT831787E (pt) 2002-02-28
IL122385A0 (en) 1998-06-15
ES2161366T3 (es) 2001-12-01
MX9709698A (es) 1998-07-31
WO1996040072A3 (en) 1997-01-23
BR9608542A (pt) 1999-11-30
CN1102854C (zh) 2003-03-12
NO975708D0 (no) 1997-12-05
DK0831787T3 (da) 2001-12-17
IL122385A (en) 2001-01-11
DE69614685T2 (de) 2002-06-27
DE69614685D1 (de) 2001-09-27
PL184531B1 (pl) 2002-11-29
CZ288147B6 (en) 2001-05-16
AU6146996A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
ATE204468T1 (de) Mittel zur verzögerten freisetzung von menschlichem wachstumshormon
MX9709699A (es) Composicion para la liberacion sostenida de eritropoyetina no agregada.
DE3853853T2 (de) Verabreichungsformen für Pharmaka.
CA2474698A1 (en) Polymer-based compositions for sustained release
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
DE69840495D1 (de) Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
WO2001058474A3 (en) Microencapsulation and sustained release of biologically active agent
JPH07187994A (ja) 薬物放出制御製剤
EP1570823A3 (de) Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin
ATE433318T1 (de) Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
ATE260651T1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
ATE315409T1 (de) Verbesserte formulierung zur gesteuerten arzneistofffreisetzung durch kombination hydrophiler und hydrophober stoffe
ATE109000T1 (de) System zur freisetzung von medikamenten und dessen herstellungsmethode.
US5342622A (en) Subdermal biocompatible implants
AU7004194A (en) Drug system
SK138096A3 (en) Collagen preparation for the controlled release of active substances
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DE19850517B4 (de) Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
KR20200099901A (ko) 피나스테라이드를 포함하는 마이크로 입자를 함유한 피하 주사용 조성물
RU97115937A (ru) Применение изосорбид-5-мононитрата

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee